Nothing Special   »   [go: up one dir, main page]

MA53489A - Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'agents thérapeutiques - Google Patents

Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'agents thérapeutiques

Info

Publication number
MA53489A
MA53489A MA053489A MA53489A MA53489A MA 53489 A MA53489 A MA 53489A MA 053489 A MA053489 A MA 053489A MA 53489 A MA53489 A MA 53489A MA 53489 A MA53489 A MA 53489A
Authority
MA
Morocco
Prior art keywords
therapeutic agents
heteroaryl substituted
sulphonamide compounds
substituted sulphonamide
compounds
Prior art date
Application number
MA053489A
Other languages
English (en)
Inventor
Jean-Christophe Andrez
Kristen Nicole Burford
Christoph Martin Dehnhardt
Thilo Focken
Michael Edward Grimwood
Qi Jia
Verner Alexander Lofstrand
Shaoyi Sun
Steven Sigmund Wesolowski
Michael Scott Wilson
Alla Yurevna Zenova
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of MA53489A publication Critical patent/MA53489A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA053489A 2018-08-31 2019-08-29 Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'agents thérapeutiques MA53489A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862725956P 2018-08-31 2018-08-31

Publications (1)

Publication Number Publication Date
MA53489A true MA53489A (fr) 2021-12-08

Family

ID=67953876

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053489A MA53489A (fr) 2018-08-31 2019-08-29 Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'agents thérapeutiques

Country Status (25)

Country Link
US (2) US10981905B2 (fr)
EP (1) EP3844150A1 (fr)
JP (1) JP7450606B2 (fr)
KR (1) KR20210054510A (fr)
CN (1) CN112638879B (fr)
AU (1) AU2019331005B2 (fr)
BR (1) BR112021000209A2 (fr)
CA (1) CA3110853A1 (fr)
CL (1) CL2021000443A1 (fr)
CO (1) CO2021001433A2 (fr)
CR (1) CR20210099A (fr)
DO (1) DOP2021000031A (fr)
EA (1) EA202190395A1 (fr)
EC (1) ECSP21013035A (fr)
IL (1) IL279810B1 (fr)
JO (1) JOP20200337A1 (fr)
MA (1) MA53489A (fr)
MX (1) MX2021001380A (fr)
NI (1) NI202100013A (fr)
PE (1) PE20211066A1 (fr)
PH (1) PH12021550381A1 (fr)
SG (1) SG11202100109TA (fr)
TW (1) TW202115018A (fr)
WO (1) WO2020047323A1 (fr)
ZA (1) ZA202100593B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3551626B1 (fr) 2016-12-09 2023-10-25 Xenon Pharmaceuticals Inc. Composés de benzènesulfonamide et leur utilisation en tant qu'agents thérapeutiques
PL3740481T3 (pl) 2018-01-19 2024-11-04 Cytokinetics, Inc. Analogi dihydrobenzofuranu i indenu jako inhibitory sarkomerów sercowych
MA52888A (fr) 2018-06-13 2021-04-21 Xenon Pharmaceuticals Inc Composés de benzènesulfonamide et leur utilisation en tant qu'agents thérapeutiques
US11964967B2 (en) 2018-06-26 2024-04-23 Cytokinetics, Inc. Cardiac sarcomere inhibitors
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
US10981905B2 (en) 2018-08-31 2021-04-20 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
TWI848972B (zh) 2018-08-31 2024-07-21 美商胞質動力學公司 心臟肌小節抑制劑
BR112023017461A2 (pt) 2021-03-04 2023-09-26 Cytokinetics Inc Compostos, composição farmacêutica, métodos de tratamento de doença cardíaca, de uma doença ou afecção associada à cardiomiopatia hipertrófica, de uma doença ou afecção que está associada ao espessamento secundário da parede do ventrículo esquerdo, de uma doença ou afecção associada à pequena cavidade ventricular esquerda e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia miocárdica ou fibrose cardíaca, de uma doença ou afecção selecionada a partir de distrofias musculares e doenças de armazenamento de glicogênio, e, método de inibição do sarcômero cardíaco
KR20240030592A (ko) * 2022-08-31 2024-03-07 주식회사 아이엔테라퓨틱스 인비보 세포외 신경다발절 기록법을 이용한 전기생리학적 약효평가법
US20250034108A1 (en) * 2023-07-07 2025-01-30 Novartis Ag Sodium channel blockers

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5877193A (en) 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
CN1184957C (zh) 1997-05-07 2005-01-19 盖伦(化学制品)有限公司 用于给药睾酮和睾酮前体的阴道内给药装置
DE69928286T2 (de) 1999-01-13 2006-07-13 Warner-Lambert Co. Llc Benzenesulfonamid-derivative und ihre verwendung als mek-inhibitoren
CA2378381A1 (fr) 1999-07-16 2001-01-25 Warner-Lambert Company Traitement de douleurs chroniques au moyen d'inhibiteurs de mek
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
FR2836917B1 (fr) 2002-03-11 2006-02-24 Lipha Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif
PL215132B1 (pl) 2002-06-27 2013-10-31 Novo Nordisk As Pochodna arylokarbonylowa jako srodek terapeutyczny, jej zastosowanie i kompozycja farmaceutyczna ja zawierajaca
WO2004092123A2 (fr) 2003-04-10 2004-10-28 Microbia, Inc. Inhibiteurs d'invasion fongique
WO2005000309A2 (fr) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Composes chimiques
CA2531418A1 (fr) 2003-07-08 2005-01-20 Novartis Ag Composes benzenesulfonylamino, et compositions pharmaceutiques contenant ces composes
KR20060073930A (ko) 2003-08-08 2006-06-29 버텍스 파마슈티칼스 인코포레이티드 통증 치료시 나트륨 또는 칼슘 채널 차단제로서 유용한헤테로아릴아미노설포닐페닐 유도체
HU227684B1 (en) 2003-08-29 2011-11-28 Sanofi Aventis Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
EP1888544A2 (fr) 2004-12-17 2008-02-20 Takeda San Diego, Inc. Inhibiteurs des hydroxystéroides déshydrogénases
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
KR20080053931A (ko) 2005-10-06 2008-06-16 사노피-아벤티스 4-옥시-ｎ-[1,3,4]-티아디아졸-2-일-벤젠 설폰아미드, 이의제조방법 및 약제로서의 이의 용도
RU2008129821A (ru) 2005-12-21 2010-01-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Гетероциклические производные в качестве модуляторов ионных каналов
WO2008019967A2 (fr) 2006-08-15 2008-02-21 F. Hoffmann-La Roche Ag Dérivés phényliques, de la pyridine et de la quinoléine
US7968556B2 (en) 2006-10-19 2011-06-28 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and methods of treatment therewith
ES2523196T3 (es) 2007-07-13 2014-11-21 Icagen, Inc. Inhibidores de los canales de sodio
EP2173743A2 (fr) 2007-07-13 2010-04-14 Icagen, Inc. Inhibiteurs des canaux sodiques
WO2009013171A2 (fr) 2007-07-24 2009-01-29 F. Hoffmann-La Roche Ag Composés antiviraux hétérocycliques
US7935779B2 (en) 2008-03-07 2011-05-03 Great Eastern Resins Industrial Co., Ltd. Synthesis of polyimides (PI) from poly-carbodiimides and dianhydrides by sequential self-repetitive reaction (SSRR)
CN102076650A (zh) 2008-06-25 2011-05-25 第一三共株式会社 羧酸化合物
WO2010002956A2 (fr) 2008-07-01 2010-01-07 Vertex Pharmaceuticals Incorporated Dérivés hétérocycliques en tant que modulateurs des canaux ioniques
GB0815947D0 (en) * 2008-09-02 2008-10-08 Univ Dundee Compounds
WO2010029300A1 (fr) 2008-09-12 2010-03-18 Biolipox Ab Composés bis-aromatiques pour utilisation dans le traitement de l’inflammation
DK2385938T3 (en) 2009-01-12 2015-04-27 Pfizer Ltd Sulfonamidderivater
CA2804593C (fr) 2010-07-09 2015-11-24 Pfizer Limited Derives de biphenyloxybenzensulphonamide utiles en tant qu'inhibiteurs du canal sodique
KR101541086B1 (ko) 2010-08-20 2015-08-03 허치슨 메디파르마 리미티드 피롤로피리미딘 화합물 및 그 용도
AU2012296529A1 (en) 2011-08-17 2014-02-20 Amgen Inc. Heteroaryl sodium channel inhibitors
WO2013063459A1 (fr) 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp. Composés de benzoxazolinone ayant une activité sélective dans des canaux sodiques voltage-dépendants
RU2014121984A (ru) 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Бензолсульфонамидные соединения и их применение в качестве терапевтических средств
RU2014121983A (ru) 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Биарильные простоэфирные сульфонамиды и их применение в качестве терапевтических средств
US8889741B2 (en) 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
WO2013122897A1 (fr) 2012-02-13 2013-08-22 Amgen Inc. Inhibiteurs des canaux sodiques de type dihydrobenzoxazine et tétrahydroquinoxaline
KR102038607B1 (ko) 2012-10-15 2019-10-30 주식회사 대웅제약 소디움 채널 차단제, 이의 제조방법 및 이의 용도
JP2015535252A (ja) 2012-10-26 2015-12-10 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 電位作動型ナトリウムチャネルにおいて選択的活性を有するｎ−置換インダゾールスルホンアミド化合物
KR20150074122A (ko) 2012-10-26 2015-07-01 머크 샤프 앤드 돔 코포레이션 전압-게이팅 나트륨 채널에서 선택적 활성을 갖는 벤족사졸리논 화합물
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
US9212182B2 (en) 2013-06-12 2015-12-15 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
GB201310542D0 (en) 2013-06-13 2013-07-31 Antabio Sas Compounds
JP6407285B2 (ja) 2013-09-09 2018-10-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＲＯＲγ調節因子
CA2922851C (fr) 2013-09-10 2023-03-14 Chromocell Corporation Modulateur des canaux sodiques pour le traitement de la douleur et du diabete
WO2015077905A1 (fr) 2013-11-29 2015-06-04 Merck Sharp & Dohme Corp. Composés de benzènesulfonamide à substitution bicycloamine ayant une activité sélective dans les canaux sodiques sensibles à la tension
WO2015099841A1 (fr) 2013-12-23 2015-07-02 Purdue Pharma L.P. Indazoles et leur utilisation
CN106795149B (zh) 2015-05-05 2019-09-24 上海海雁医药科技有限公司 双环取代的苯磺酰胺衍生物、其制法与医药上的用途
BR112018012327A2 (pt) 2015-12-18 2018-12-04 Merck Sharp & Dohme compostos de diamina-arilsulfonamida substituídos com hidroxialquilamina e hidroxicicloalquilamina com atividade seletiva em canais de sódio ativados por voltagem
CN109069489A (zh) 2015-12-18 2018-12-21 默沙东公司 对电压门控性钠通道具有选择性活性的二氨基-烷基氨基连接的芳基磺酰胺化合物
HUE051348T2 (hu) 2016-05-03 2021-03-01 Bayer Pharma AG Aromás szulfonamid származékok
CN109526219B (zh) 2016-05-20 2021-03-12 泽农医药公司 苯磺酰胺及其作为治疗剂的用途
EP3541373B1 (fr) 2016-11-17 2023-11-01 Merck Sharp & Dohme LLC Composés d'arylsulfonamide à liaisons diamino-alkylamino présentant une activité sélective dans les canaux sodiques sensibles à la tension
EP3551626B1 (fr) * 2016-12-09 2023-10-25 Xenon Pharmaceuticals Inc. Composés de benzènesulfonamide et leur utilisation en tant qu'agents thérapeutiques
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
MA52888A (fr) 2018-06-13 2021-04-21 Xenon Pharmaceuticals Inc Composés de benzènesulfonamide et leur utilisation en tant qu'agents thérapeutiques
US10981905B2 (en) 2018-08-31 2021-04-20 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
CN112638898B (zh) 2018-08-31 2024-04-09 泽农医药公司 杂芳基取代的磺酰胺化合物及其作为钠通道抑制剂的用途
TWI848972B (zh) 2018-08-31 2024-07-21 美商胞質動力學公司 心臟肌小節抑制劑

Also Published As

Publication number Publication date
CO2021001433A2 (es) 2021-05-10
CN112638879B (zh) 2024-06-18
PE20211066A1 (es) 2021-06-09
KR20210054510A (ko) 2021-05-13
WO2020047323A1 (fr) 2020-03-05
CA3110853A1 (fr) 2020-03-05
NI202100013A (es) 2021-06-22
AU2019331005B2 (en) 2024-03-28
US10981905B2 (en) 2021-04-20
TW202115018A (zh) 2021-04-16
ZA202100593B (en) 2023-10-25
JP2021535134A (ja) 2021-12-16
BR112021000209A2 (pt) 2021-08-24
SG11202100109TA (en) 2021-02-25
CL2021000443A1 (es) 2021-07-02
CN112638879A (zh) 2021-04-09
AU2019331005A1 (en) 2021-02-18
US20220348570A1 (en) 2022-11-03
CR20210099A (es) 2021-06-24
EA202190395A1 (ru) 2021-06-15
MX2021001380A (es) 2021-05-27
JP7450606B2 (ja) 2024-03-15
US11639351B2 (en) 2023-05-02
DOP2021000031A (es) 2021-03-31
IL279810B1 (en) 2024-11-01
JOP20200337A1 (ar) 2020-12-24
US20200157089A1 (en) 2020-05-21
EP3844150A1 (fr) 2021-07-07
ECSP21013035A (es) 2021-03-31
PH12021550381A1 (en) 2021-12-13
IL279810A (en) 2021-03-01

Similar Documents

Publication Publication Date Title
MA53489A (fr) Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'agents thérapeutiques
MA48583A (fr) Composés de benzènesulfonamide et leur utilisation en tant qu'agents thérapeutiques
MA52888A (fr) Composés de benzènesulfonamide et leur utilisation en tant qu'agents thérapeutiques
MA53488A (fr) Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques
MA52189A (fr) Benzothiophènes et composés associés utilisés en tant qu'agonistes de sting
MA48765A (fr) Cyanopyrrolidines substituées par sulfonamide ayant une activité en tant qu'inhibiteurs de dub
MA53221A (fr) Nouveaux composés de sulfonamide urée
MA45377A (fr) Composés hétérocycliques en tant qu'agents antibacteriens
MA53172A (fr) Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
MA51232A (fr) Indane-amines utiles en tant qu'antagonistes de pd-l1
EP3405116A4 (fr) Applicateur endoscopique d'agrafes chirurgicales
EP3250035A4 (fr) Composés et leur utilisation en tant qu'inhibiteurs de bace1
EP4000451C0 (fr) Masque cosmétique pour les yeux
MA56183A (fr) Pyrazolo-pyridines hétéroaromatiques substituées et leur utilisation en tant que modulateurs du récepteur glun2b
MA49017A (fr) Modulateurs du récepteur 7 de la 5-hydroxytryptamine et utilisation de ces derniers en tant qu'agents thérapeutiques
MA52244A (fr) Pyridine et pyrimidines substituées et leur utilisation en tant que modulateurs du récepteur glun2b
MA51224A (fr) Composés de sulfonamide et leur utilisation
EP3334719A4 (fr) Benzimidazoles substitués, préparation et utilisation de ceux-ci en tant qu'agents pharmaceutiques
MA45917A (fr) Sulfonamides en tant qu'agonistes de gpr40 et gpr120
MA48942A (fr) Composés thérapeutiques, compositions et procédés d'utilisation associés
EP3849664C0 (fr) Composés phénoxy-pyridyl-pyrimidine et méthodes d'utilisation associées
MA53479A (fr) Composés hétérocycliques en tant q'inibiteurs de vanin
MA46896A (fr) Composés d'alcène tétrasubstitués et leur utilisation
MA49374A (fr) Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine
EP3664721C0 (fr) Applicateur d'agrafes chirurgicales